Skip to main content
. 2019 Feb 8;30(2):139–154. doi: 10.1089/hum.2018.020

Figure 2.

Figure 2.

Tafazzin protein expression comparisons between AAV-TAZ vectors following delivery to adult or neonatal TazKD mice. (A) Representative Western blot analyses using (1) α-Myc antibody, (2) α-tafazzin antibody, (3) GAPDH control antibody on whole heart lysates, or (4) α-Myc antibody on Myc-bead purified (pulldown) heart lysate samples. (B) Graph depicting tafazzin/GAPDH Western blot density ratios for whole heart lysate samples. Data are represented as Mean ± SEM (n = 3 biological replicates). Significant differences between promoters for each treatment age are indicated by lines above bars and significant improvement between each individual sample and untreated TazKD controls is indicated at the bottom of bars (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). (C–J) Immunofluorescence analyses of the MTCO2 mitochondrial protein (left panel for each) and the Myc tag (middle panel for each) and an overlay of the two including DAPI in blue (right panel for each) shows no Myc expression in WT (C) or TazKD (D) mouse heart sections and varying levels of expression in hearts representing mice from all treatment cohorts: CMV-TAZad (E); CMV-TAZneo (F); Des-TAZad (G); Des-TAZneo (H); Taz-TAZad (I); and Taz-TAZneo (J).